S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2012 Financial Results (2013/3/18)|
|Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results (2013/5/10)|
|Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R) (2013/3/27)|
|Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University (2013/4/29)|
|Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents (2013/4/10)|
|Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference (2013/4/29)|
|Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule (2013/5/2)|
|Repros Therapeutics Corporate Update (2013/2/11)|
|Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal(R) to be Completed as Originally Planned (2013/2/21)|
|FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 3 Study Design (2013/2/28)|
Click above to view more mutual fund data and stats for rprx - Repros Therapeutics, Inc..